Acute respiratory distress syndrome (ARDS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Acute Respiratory Distress Syndrome (ARDS)

Acute respiratory distress syndrome (ARDS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

ARDS caused by  infection in the blood (sepsis) most common type; serious injury to the head or chest, or severe bleeding; infection in the lungs (pneumonia); blood transfusions; Inhaling vomit; Breathing toxic fumes or smoke.

Thelansis Epidemiology study indicates there are about 200,000 cases of ARDS each year in the United States.

Competitive landscape of ARDS includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of ARDS across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

ARDS Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

Read more: Acute respiratory distress syndrome (ARDS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Stage

1        RLF-100        Relief Therapeutics        Phase 3

2        Gimsilumab        Roivant Sciences, Inc.        Phase 2

3        HLCM051        Histocell, S.L.        Phase 2

4        Veru-111        Veru Inc.        Phase 2

5        Drug: AeroFact        Aerogen Pharma Limited        Phase 2

6        CERC-002        Cerecor Inc        Phase 2

7        Remestemcel-L        Mesoblast, Inc.        Phase 3

8        Lucinactant for Inhalation        Windtree Therapeutics        Phase 2

9        TD-0903        Theravance Biopharma        Phase 2

10        APL-9        Apellis Pharmaceuticals, Inc.        Phase 2

11        Aviptadil by intravenous infusion + standard of care        NeuroRx, Inc.        Phase 2

12        Dociparastat sodium        Chimerix        Phase 3

13        MultiStem        Athersys, Inc        Phase 3

14        Centricyte 1000        Healeon Medical Inc        Phase 1

15        Inhaled ILOPROST        Hamad Medical Corporation        Phase 2

16        REGN10933+REGN10987 combination therapy        Regeneron Pharmaceuticals        Phase 2

17        ATYR1923 1 mg/kg        aTyr Pharma, Inc.        Phase 2